HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ryan, J. Articles by Kisiel, W. Search for Related Content PubMed PubMed Citation Articles by Ryan, J. Articles by Kisiel, W. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 264, Issue 34, 20283-20287, Dec, 1989

Structural determinants of the factor IX molecule mediating interaction with the endothelial cell binding site are distinct from those involved in phospholipid binding

J Ryan, B Wolitzky, E Heimer, T Lambrose, A Felix, JP Tam, LH Huang, P Nawroth, G Wilner and W Kisiel
Department of Physiology and Cellular Biophysics, Columbia University, New York, New York 10032.

Previous studies have indicated that Factor IX/IXa interacts in a specific and high affinity manner with a binding site on the endothelial cell surface. In this study, the contributions of the gamma- carboxyglutamic acid-containing (GLA) and growth factor domains to the finding of Factor IX to the endothelium were assessed. While GLA- containing peptides from Factors IX, X, and prothrombin were inhibitors of 125I-Factor IX-endothelial cell binding, the GLA peptide from Factor IX was about 250-800-fold more effective than those from prothrombin and Factor X, respectively. In contrast to its relative efficacy as an inhibitor of Factor IX-cell surface interaction, the Factor IX-GLA peptide neither bound to lipid vesicles nor inhibited Factor IX-lipid interaction. A synthetic peptide comprising the entire first epidermal growth factor (EGF) exon was also an inhibitor of 125I-Factor IX- endothelial cell binding, although it did not interact with lipid vesicles. Experiments with synthetic peptides comprising each of the three loops of the first EGF domain or the entire first EGF region with specific substitutions indicated the importance of determinants in both the first and probably third loops for Factor IX-endothelial interaction. In contrast, the second loop of the first EGF domain and the first loop of the second EGF exon are probably not involved in Factor IX-endothelial interaction based on their inability to block 125I-Factor IX binding to cells. These results indicate that determinants in both the GLA and the first EGF domain contribute to the specific binding of Factor IX to the endothelial cell surface and that structural requirements for Factor IX-cell surface interaction are distinct from those for Factor IX binding to lipids.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. Kirchhofer, T. B. Tschopp, and H. R. Baumgartner Active Site–Blocked Factors VIIa and IXa Differentially Inhibit Fibrin Formation in a Human Ex Vivo Thrombosis Model Arterioscler. Thromb. Vasc. Biol., August 1, 1995; 15(8): 1098 - 1106. [Abstract] [Full Text]

				K. Kuwabara, D. J. Pinsky, A. M. Schmidt, C. Benedict, J. Brett, S. Ogawa, M. J. Broekman, A. J. Marcus, R. R. Sciacca, M. Michalak, et al. Calreticulin, an Antithrombotic Agent Which Binds to Vitamin K-dependent Coagulation Factors, Stimulates Endothelial Nitric Oxide Production, and Limits Thrombosis in Canine Coronary Arteries J. Biol. Chem., April 7, 1995; 270(14): 8179 - 8187. [Abstract] [Full Text] [PDF]